Farxiga and Chronic Kidney Disease: Trial Stopped Early for Extremely Positive Result

[Northerner]

AstraZeneca announced that the DAPA-CKD trial was stopped many months early because strong data showed that Farxiga prevents chronic kidney disease (CKD) from getting worse. CKD is a common diabetes complication that can be excruciating for people with diabetes – it is major news that a medicine can be used to prevent or treat it. Farxiga is now the first SGLT-2 inhibitor drug to show important benefit in people who have CKD both with and without type 2 diabetes.

The trial, which enrolled 4,000 patients with CKD, including both people with and without type 2 diabetes, was initially expected to end in November 2020. The early stop comes after a regular assessment found the incredibly positive benefit of Farxiga.

Farxiga and Chronic Kidney Disease: Trial Stopped Early for Extremely Positive Result

Early trial results found that SGLT-2 inhibitor Farxiga is highly effective for preventing and treating kidney disease in people with or without type 2 diabetes

diatribe.org

 

[everydayupsanddowns]

Interesting results Northie.

Hope the results are confirmed, and it goes into help lots of people.

The trial I’m involved in as PPI chair is having to make adjustments to adapt to the pandemic, so that the follow up data can be collected

 

[Davein]

AstraZeneca announced that the DAPA-CKD trial was stopped many months early because strong data showed that Farxiga prevents chronic kidney disease (CKD) from getting worse. CKD is a common diabetes complication that can be excruciating for people with diabetes – it is major news that a medicine can be used to prevent or treat it. Farxiga is now the first SGLT-2 inhibitor drug to show important benefit in people who have CKD both with and without type 2 diabetes.

The trial, which enrolled 4,000 patients with CKD, including both people with and without type 2 diabetes, was initially expected to end in November 2020. The early stop comes after a regular assessment found the incredibly positive benefit of Farxiga.

Farxiga and Chronic Kidney Disease: Trial Stopped Early for Extremely Positive Result

Early trial results found that SGLT-2 inhibitor Farxiga is highly effective for preventing and treating kidney disease in people with or without type 2 diabetes

diatribe.org

Do you know if this is the same drug as Forxiga (dapagliflozin)? Seems strange to me that two drugs if the same would have one letter spelling difference but then as it's .in the same family of drugs perhaps not so strange

 

[Contused]

Apparently…

Dapagliflozin
Dapagliflozin, sold under the brand name Farxiga among others, is a medication used to treat type 2 diabetes and, with certain restrictions, type 1 diabetes. It is of the gliflozin class. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Wikipedia
Pronunciation:- ə-glif - zin ]]
Trade names:Forxiga, Farxiga, others

 

[Northerner]

Apparently…

Dapagliflozin
Dapagliflozin, sold under the brand name Farxiga among others, is a medication used to treat type 2 diabetes and, with certain restrictions, type 1 diabetes. It is of the gliflozin class. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca.Wikipedia
Pronunciation:- ə-glif - zin ]]
Trade names:Forxiga, Farxiga, others

I thought the flozins were supposed to potentially cause problems with the kidneys, particularly with UTIs, as they work by flushing excess glucose out through them

 

[mikeyB]

Nonetheless, you can’t fault the trial. The drug they used is identical to the wee producer that’s used in diabetes. Might not be a great idea for diabetes, but it seems to be a great move in renal failure.